Aspergillus assay kit

serumlateral flow

Over 30 million people are at risk of invasive aspergillosis each year due to use of corticosteroids, chemotherapy or other immunosuppressive agents, and over 300,000 patients develop it annually. 1 Timely diagnosis and initiation of therapy strongly influence outcome. IMMY’s lateral flow assay can detect Aspergillus biomarkers in under an hour. Clinical Relevancy2,3 Asp LFA Publication Findings The clinical performance of the IMMY sona Aspergillus Lateral Flow Assay in serum samples from cases classified as proven/probable/chronic IA/IFD (n=32) using EORTC/MSG criteria and control patients with no evidence of IFD (n=100). 2) Lewis W., et al. An evaluation of the performance of the IMMY sōna Aspergillus GM LFA when testing serum to aid in the diagnosis of IA. J Clin Micro. 2020; 00053-20. In serum samples, the AGM LFA will correctly generate a positive result for 97% of patients with IA, and a negative result for 98% of patients without IA. The PPV shows that among patients with a positive AGM LFA result, the probability that they truly have IA is 94%. NPV shows that among patients with a negative AGM LFA result, the probability that they do not have IA is 99%. 2 Asp LFA Publication Findings The diagnostic performance of the IMMY sona Aspergillus Lateral Flow Assay in BAL samples from hematology patients classified as proven IPA (n=11) using EORTC/MSG criteria and control patients with no evidence of IPA (n=117). 3) Mercier T, et al. Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: A comparative multicenter study. Med Mycol. 2019.